Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth hormone and aging.

C J Rosen1

  • 1The Maine Center for Osteoporosis Research and Education, St. Joseph Hospital, Bangor 04401, USA. Rofe@aol.com

Endocrine
|July 25, 2000
PubMed
Summary
This summary is machine-generated.

Aging reduces growth hormone secretion, impacting IGF-I levels. While growth hormone therapy benefits some, its effects in the elderly are limited and may increase cancer risk, reducing enthusiasm for reversal.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IGF-1 is associated with estimated bone strength in anorexia nervosa.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Clinical implications of bone marrow adiposity.

Journal of internal medicine·2017
Same author

Type 2 Diabetes and Aging: A Not so Sweet Scenario for Bone.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2016
Same author

HP1BP3 expression determines maternal behavior and offspring survival.

Genes, brain, and behavior·2016
Same author

PPARG Post-translational Modifications Regulate Bone Formation and Bone Resorption.

EBioMedicine·2016
Same author

Daily leptin blunts marrow fat but does not impact bone mass in calorie-restricted mice.

The Journal of endocrinology·2016

Area of Science:

  • Endocrinology
  • Gerontology
  • Metabolic research

Background:

  • Aging significantly decreases growth hormone (GH) secretion, leading to lower insulin-like growth factor-I (IGF-I) and altered IGF-binding proteins.
  • GH replacement therapy improves quality of life and body composition in GH-deficient individuals.
  • Previous studies on GH therapy in the elderly yielded disappointing results, with minimal improvements in lean mass and function.

Purpose of the Study:

  • To review the effects of declining growth hormone and IGF-I in aging.
  • To evaluate the efficacy and risks of growth hormone therapy in the elderly population.
  • To discuss the future prospects of addressing age-related hormonal changes.

Main Methods:

  • Literature review of studies on growth hormone, IGF-I, and aging.

Related Experiment Videos

  • Analysis of clinical trial data regarding GH therapy in elderly individuals.
  • Examination of recent evidence linking IGF-I levels to neoplastic disorders.

    • Main Results:

    • GH therapy in the elderly showed limited benefits for lean body mass, musculoskeletal function, and quality of life.
    • High normal serum IGF-I levels are potentially associated with an increased risk of certain cancers.
    • The concept of reversing age-related hormonal decline (somatopause) with recombinant growth factors faces reduced enthusiasm.

    Conclusions:

    • The benefits of growth hormone therapy in the elderly are questionable due to minimal efficacy and potential cancer risks.
    • Further research is needed to understand the complex role of IGF-I in aging and disease.
    • Alternative strategies may be required to address the physiological changes associated with aging and somatopause.